After spending much of the past year in the shadow of greatness at a four-star rank, Myriad Genetics
Despite an unfavorable patent ruling and earnings miss earlier this year, more CAPS members have warmed up to Myriad Genetics' stock and believe shares are sitting at an attractive valuation today. Similar to peer Hologic
The momentum of other diagnostic test makers may be a good sign for Myriad's business. Abbott Labs
Do you think Myriad Genetics deserves its raised status? Add your thoughts in the comments box below on this page, or head over to CAPS to rate the company and check out all the information and opinions the community offers, absolutely free.
Always looking ahead, the Motley Fool Rule Breakers service is picking the next generations' big winners today. To see what other rule-breaking stocks David Gardner is recommending now, take a free 30-day trial.
Fool contributor Dave Mock recently upgraded his refrigerator with more dazzling kid art. He owns no shares of companies mentioned here. MedcoHealth Solutions is a Stock Advisor pick. The Fool owns shares of GlaxoSmithKline. The Fool's disclosure policy always signals before changing lanes.